|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 655 15th St, NW |
Address2 | Suite 503 |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: James Williams |
Date | 4/22/2024 1:06:49 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, cancer survivorship, federal health care programs, genetic information, cancer, nutrition, tanning
beds, clinical trials, skin cancer, cannabis research, and wellness, including:
The Inflation Reduction Act - extension of expanded tax credits for ACA marketplaces;
The Prevent HPV Cancers Act
Women and Lung Cancer Research and Preventive Services Act of 2021
Gabriella Miller Kids First Research Act 2.0 (H.R. 623/S. 1523)
The Palliative Care and Hospice Education and Training Act
Provider Training in Palliative Care Act
Issues related to the possible introduction of the 21st Century Cures Act version 2.0
Regulations implementing the No Surprises Act
Proposed Rule on Affordability of Employer Coverage for Family Members of Employees, REG-114339-21
Regulations related to short term limited duration health insurance plans (upcoming)
OMB RFI on health equity - comments
DICT RFI - Eshoo
DICT Ancillary Costs legislation/Menendez, Scott, Smith, Young, Ruiz
House/Senate Appropriations Committee FDA DICT report language
Reducing Hereditary Cancer Act - DWS, Slotkin, Miller-Meeks, and Davis
Personal Care Products Safety Act
Reducing COVID-19 Disparities by Investing in Public Health Act of 2021
The VALID Act
Modernization of Clinical Trials Act
DEPICT Act
NIH Clinical Trials Diversity Act
Food and Drug Amendments Act
Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act
Retaining Access and Restoring Exclusivity (RARE) Act
Health Equity and Accountability Act
Notice of Benefit and Payment Parameters, regulatory comments
Regulatory issues related to healthy food and dietary guidelines
Help CoPays Act
Compact Fairness Act
Nancy Gardner Sewell Multi-Cancer Early Detection Act
PSA for HIM Act
PC CARE Act
Alan Reinstein Ban Asbestos Act
Firefighter Cancer Registry Act
DOD Directed Medical Research Program
Childhood Cancer STAR Act
H.R. 3810, the Drug Origin Transparency Act of 2023,
H.R. 3008, the Drug Shortage Prevention Act,
H.R. 2500, the Protecting Americans from Unsafe Drugs Act of 2023
H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023
H.R. 3807, the Medical Device Shortage Reduction Act of 2023,
H.R. 405, Essential Medicines Strategic Stockpile Act of 2023
Comprehensive Cancer Survivorship Act (S.2213 H bill number TBD):
Safe Step Act
Cancer Drug Parity Act (S.2039 - Cancer Drug Parity Act of 2023; H.R. 6301 Cancer Drug Parity Act of 2023)
Equitable Community Access to Pharmacist Services Act
PBM Reform
340B Reform
Medical Nutrition Act
Drug Shortages
The Screening for Communities to Receive Early and Equitable Needed Services (SCREENS for Cancer) Act - H.R. 3916 - SCREENS for Cancer Act of 2023
Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers (PREVENT) Act - H.R. 3633 PREVENT HPV Cancers Act of 2023; Promotion Resources to Expand Vaccination, Education and New Treatment for HPV Cancers Act of 2023
Access to Breast Cancer Diagnosis Act of 2023
Find It Early Act - H.R. 3086
Henrietta Lacks Congressional Gold Medal Act
Creating Opportunities Now for Necessary and Effective Technologies (CONNECT) for Health Act of 2023
Accelerating Kids Access to Care Act- S.2372; H.R. 4758
RAPID Reserve Act (S. 2510)
Energy & Commerce Majority Drug Shortage RFI
Energy & Commerce Majority/Finance Minority Drug Shortage RFI
House Budget Committee RFI on how to reduce healthcare spending
Telehealth Benefit Expansion for Workers Act (H.R. 824)
Multi-Cancer Early Detection Act
Women and Lunch Cancer Research and Preventative Services Act
Lung Cancer Screening and Prevention Act
Veterans Counting Cancer Act
Harley Jacobsen Clinical Trial Participant Income Exemption Act (H.R. 7090)
Creating Hope Reauthorization Act of 2024 (H.R. 7384)
The Pediatric Cancer Drug Supply Act of 2024 (H.R. 6963)
The Counting Veterans Cancer Act of 2023 (S. 1994)
Lung Cancer Screening and Prevention Act (H.R. 6693)
Health Equity Accountability Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL), Food & Drug Administration (FDA), White House Office, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Nickson |
|
Chief of Staff, U.S. Representative Barbara Lee (D-CA 13) (2002 - 2022) |
|
James |
Williams |
Jr. |
Deputy Chief of Staff & Appropriations Staff, U.S. Representative Carolyn Kilpatrick (D - MI 13) (2005 - 2010); Legislative Director, Rep. Frederica Wilson (D - FL 24) (2011) |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Angela |
Sailor |
|
|
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern, Senator Barack Obama (D-IL)(2005). |
|
Jelani |
Murrain |
|
Legislative Correspondent, U.S. Senator John D. Rockefeller, IV (D-WV) (2002-2003); Intern, U.S. Representative John Lewis (D-GA 5) (2003) |
|
Marc |
Gottschalk |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues regarding expanding the availability of the charitable deduction for non-itemizers, issues respecting charitable giving and life income planning, issues regarding taxation of charitable organizations, and issues regarding economic relief for nonprofit organizations.
Issues related to stimulus for nonprofit organizations and increasing charitable giving.
Legacy IRA Act.
Modernization of Clinical Trials Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Treasury - Dept of, Small Business Administration (SBA), Federal Reserve System
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jelani |
Murrain |
|
Legislative Correspondent, U.S. Senator John D. Rockefeller, IV (D-WV) (2002-2003); Intern, U.S. Representative John Lewis (D-GA 5) (2003) |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Angela |
Sailor |
|
|
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern,Senator Barack Obama (D-IL)(2005). |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, age of sale of tobacco products, tobacco taxes, graphic warning labels, product regulation, and smoke-free environments, including:
Implementation of the Family Smoking Prevention and Tobacco Control Act, including the FDA deeming regulation;
Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars;
The Quit Because of COVID-19 Act (Helping Tobacco Users Quit Act)
The PROTECT Act
Increasing Access to Lung Cancer Screening Act (H.R. 4286)
Helping Tobacco Users Quit Act (H.R. 4775)
Tobacco Tax Equity Act of 2023 (H.R. 5715/S. 2929)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Williams |
Jr. |
Deputy Chief of Staff & Appropriations Staff, U.S. Representative Carolyn Kilpatrick (D - MI 13) (2005 - 2010); Legislative Director, Rep. Frederica Wilson (D - FL 24) (2011) |
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern, Senator Barack Obama (D-IL)(2005). |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY24 Appropriations bills.
FY24 Appropriations Bills - legislation providing federal funding for all agencies with focus on cancer research and prevention funding.
Implementation of the Family Smoking Prevention and Tobacco Control Act, including the FDA deeming regulation;
Issues relating to FDA regulation of menthol, flavors, electronic cigarettes and cigars;
The Quit Because of COVID-19 Act (Helping Tobacco Users Quit Act)
FY24 House Labor, Health and Human Services legislation - NIH, NCI, CDC DCPC, and OSH funding.
FY24 Defense Appropriations for cancer programs with CDMRP
FY24 VA Appropriations for PACT Act Funding
FY24 Interior Appropriations for Indian Health Services funding
FY25 Federal Appropriations for House Labor Health and Human Services legislation (NIH, NCI, CDC, DCPC, and OSH funding)
FY25 Defense Appropriations for cancer programs with CDMRP
FY25 Interior Appropriations for Indian Health Services funding
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Defense - Dept of (DOD), U.S. Agency for International Development (USAID), Indian Health Service
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Nickson |
|
Chief of Staff, U.S. Representative Barbara Lee (D-CA 13) (2002 - 2022) |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Angela |
Sailor |
|
|
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern, Senator Barack Obama (D-IL)(2005). |
|
Marc |
Gottschalk |
|
|
|
Jelani |
Murrain |
|
Legislative Correspondent, U.S. Senator John D. Rockefeller, IV (D-WV) (2002-2003);
Intern, U.S. Representative John Lewis (D-GA 5) (2003) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to implementation of legislative or regulatory changes to Medicare and Medicaid, including:
Advancing Telehealth Beyond COVID-19 Act of 2021
Patient Navigation Assistance Act (soon to be introduced), Rep. DeSaulnier
Cancer survivorship legislation, (soon to be introduced) Rep. Wasserman Schultz
The Inflation Reduction Act - Medicaid Coverage Gap fix (not included in the legislation), cap on out-of-pocket expenses for Medicare Part D
Multi Cancer Early Detection Screening Coverage Act
Safe Step Act
To amend title XVIII of the Social Security Act to eliminate the coinsurance requirement for certain colorectal cancer screening tests furnished under the Medicare program.
Issues related to governance of state Medicaid programs, including work requirements and block grant proposals.
Policy issues related to coverage for low-income populations in states that have not yet expanded their Medicaid programs (coverage gap)
CONNECT Act (telehealth)
Lymphedema Treatment Act
Bipartisan Seniors Prescription Drug Relief Act - Cassidy/Menendez
Expanding Access to Affordable Prescription Drugs and Medical Devices Act - Rosen
Accelerating Kids Access to Care Act
Regulations related to the Public Charge Rule & Medicaid - DHS Docket No. USCIS-2021-0013, the notice of proposed rulemaking, Public Charge Ground of Inadmissibility
Public Health Emergency Extension
Advocacy around cost sharing for follow on colonoscopy after a positive at home test with CMS, related to Medicare coverage
Medical Unwinding/End of Continuous Medicaid Coverage
Lung Cancer Screening and Prevention Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Williams |
Jr. |
Deputy Chief of Staff & Appropriations Staff, U.S. Representative Carolyn Kilpatrick (D - MI 13) (2005 - 2010); Legislative Director, Rep. Frederica Wilson (D - FL 24) (2011) |
|
Jelani |
Murrain |
|
Legislative Correspondent, U.S. Senator John D. Rockefeller, IV (D-WV) (2002-2003); Intern, U.S. Representative John Lewis (D-GA 5) (2003) |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern,Senator Barack Obama (D-IL)(2005). |
|
Angela |
Sailor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Modernization of Clinical Trials Act
Gabriella Miller Kids First Research Act 2.0
Issues related to the possible introduction of the 21st Century Cures Act version 2.0
DICT RFI - Eshoo
DICT Ancillary Costs legislation/Menendez, Scott, Smith, Young, Ruiz
House/Senate Appropriations Committee FDA DICT report language
DEPICT Act
Food and Drug Amendments Act
Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act
NIH Clinical Trial Diversity Act 2023 H.R. 3503 and S.1701
Multi Cancer Early Detection Screening Coverage Act
The Alan Reinstein Ban Asbestos Act S1609/HR 2402
The Firefighter Cancer Registry Reauthorization Act of 2023 H.R.3821
Harley Jacobsen Clinical Trial Participant Income Exemption Act (H.R. 7090)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Williams |
Jr. |
Deputy Chief of Staff & Appropriations Staff, U.S. Representative Carolyn Kilpatrick (D - MI 13) (2005 - 2010); Legislative Director, Rep. Frederica Wilson (D - FL 24) (2011) |
|
Jelani |
Murrain |
|
Legislative Correspondent, U.S. Senator John D. Rockefeller, IV (D-WV) (2002-2003); Intern, U.S. Representative John Lewis (D-GA 5) (2003) |
|
Angela |
Sailor |
|
|
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1) (2007-2023);
Intern, Senator Barack Obama (D-IL) (2005) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Defense appropriations.
17. House(s) of Congress and Federal agencies Check if None
Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern, Senator Barack Obama (D-IL)(2005). |
|
James |
Williams |
Jr. |
Deputy Chief of Staff & Appropriations Staff, U.S. Representative Carolyn Kilpatrick (D - MI 13) (2005 - 2010); Legislative Director, Rep. Frederica Wilson(D - FL 24) (2011) |
|
Julie |
Nickson |
|
Chief of Staff, U.S. Representative Barbara Lee (D-CA 13) (2002 - 2022) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IND
16. Specific lobbying issues
Issues relating to Indian Health Services and the Congressional Native American Caucus.
17. House(s) of Congress and Federal agencies Check if None
Indian Health Service, U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Angela |
Sailor |
|
|
|
Nishith |
Pandya |
|
Chief of Staff, U.S. Representative Bobby L. Rush (D-IL 1)(2007-2023); Intern, Senator Barack Obama (D-IL)(2005). |
|
Tammy |
Boyd |
|
Legislative Director, U.S. Representative John Lewis (D-GA 5) (2002 - 2004) |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |